Pfizer Inc. (PFE) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Drug Manufacturers - General
EV/EBITDA
↓
10.31
↓-16% vs avg
5yr avg: 12.31
30Y Low5.9·High39.1
P/FCF
↑
15.81
↓-10% vs avg
5yr avg: 17.57
30Y Low6.9·High135.7
P/B Ratio
↓
1.65
↓-34% vs avg
5yr avg: 2.52
30Y Low1.3·High21.9
ROE
↓
8.9%
↑-50% vs avg
5yr avg: 17.6%
30Y Low2%·High48%
Debt/EBITDA
↑
3.31
+14% vs avg
5yr avg: 2.90
30Y Low0.4·High6.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PFE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Pfizer Inc. trades at 18.5x earnings, 33% below its 5-year average of 27.9x, sitting at the 47th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 16%. On a free-cash-flow basis, the stock trades at 15.8x P/FCF, 10% below the 5-year average of 17.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $143.5B | $141.6B | $151.2B | $164.4B | $293.8B | $337.1B | $207.3B | $210.8B | $247.3B | $208.0B | $189.6B |
| Enterprise Value | $209.7B | $207.9B | $217.2B | $232.4B | $328.2B | $372.1B | $243.8B | $260.5B | $287.9B | $249.2B | $228.1B |
| P/E Ratio → | 18.54 | 18.31 | 18.82 | 77.56 | 9.37 | 15.22 | 22.64 | 12.95 | 22.18 | 9.76 | 26.32 |
| P/S Ratio | 2.29 | 2.26 | 2.38 | 2.76 | 2.93 | 4.15 | 4.98 | 5.12 | 4.61 | 3.96 | 3.59 |
| P/B Ratio | 1.65 | 1.63 | 1.71 | 1.84 | 3.06 | 4.35 | 3.27 | 3.32 | 3.88 | 2.90 | 3.17 |
| P/FCF | 15.81 | 15.60 | 15.38 | 34.29 | 11.28 | 11.28 | 17.85 | 21.09 | 18.14 | 14.59 | 13.64 |
| P/OCF | 12.26 | 12.10 | 11.87 | 18.89 | 10.04 | 10.35 | 14.39 | 16.74 | 15.63 | 12.63 | 11.93 |
P/E links to full P/E history page with 30-year chart
PFE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Pfizer Inc.'s enterprise value stands at 10.3x EBITDA, 16% below its 5-year average of 12.3x. The Healthcare sector median is 14.2x, placing the stock at a 27% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.32 | 3.41 | 3.90 | 3.27 | 4.58 | 5.85 | 6.33 | 5.37 | 4.74 | 4.32 |
| EV / EBITDA | 10.31 | 10.22 | 9.24 | 20.06 | 7.70 | 14.32 | 17.71 | 19.58 | 13.29 | 12.06 | 11.39 |
| EV / EBIT | 13.59 | 20.40 | 19.54 | 71.12 | 9.13 | 14.53 | 28.73 | 19.95 | 21.81 | 18.36 | 23.92 |
| EV / FCF | — | 22.90 | 22.08 | 48.48 | 12.61 | 12.46 | 21.00 | 26.06 | 21.12 | 17.49 | 16.41 |
PFE Profitability
Margins and return-on-capital ratios measuring operating efficiency
Pfizer Inc. earns an operating margin of 24.7%. Operating margins have expanded from 8.9% to 24.7% over the past 3 years, signaling improving operational efficiency. ROE of 8.9% is modest. ROIC of 7.5% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.3% | 70.3% | 65.8% | 50.9% | 61.9% | 57.7% | 71.7% | 69.3% | 70.2% | 70.0% | 69.8% |
| Operating Margin | 24.7% | 24.7% | 25.9% | 8.9% | 37.4% | 25.6% | 21.8% | 18.2% | 28.5% | 27.4% | 27.0% |
| Net Profit Margin | 12.4% | 12.4% | 12.6% | 3.6% | 31.3% | 27.2% | 22.0% | 39.5% | 20.8% | 40.5% | 13.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 8.9% | 8.9% | 9.0% | 2.3% | 36.2% | 31.4% | 14.4% | 25.6% | 16.5% | 32.4% | 11.6% |
| ROA | 3.7% | 3.7% | 3.6% | 1.0% | 16.6% | 13.2% | 5.7% | 10.0% | 6.7% | 12.4% | 4.3% |
| ROIC | 7.5% | 7.5% | 7.9% | 2.8% | 23.2% | 14.7% | 6.4% | 5.2% | 10.6% | 10.2% | 10.8% |
| ROCE | 9.0% | 9.0% | 9.4% | 3.2% | 25.6% | 15.6% | 7.0% | 5.8% | 11.4% | 10.2% | 10.2% |
PFE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Pfizer Inc. carries a Debt/EBITDA ratio of 3.3x, which is moderately leveraged (roughly in line with the sector average of 3.2x). Net debt stands at $66.3B ($67.4B total debt minus $1.1B cash). Interest coverage of 3.8x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.78 | 0.78 | 0.76 | 0.79 | 0.36 | 0.48 | 0.60 | 0.80 | 0.65 | 0.59 | 0.69 |
| Debt / EBITDA | 3.31 | 3.31 | 2.85 | 6.12 | 0.82 | 1.42 | 2.78 | 3.82 | 1.93 | 2.06 | 2.05 |
| Net Debt / Equity | — | 0.76 | 0.75 | 0.76 | 0.36 | 0.45 | 0.57 | 0.78 | 0.64 | 0.58 | 0.64 |
| Net Debt / EBITDA | 3.26 | 3.26 | 2.81 | 5.87 | 0.81 | 1.35 | 2.65 | 3.74 | 1.87 | 2.00 | 1.92 |
| Debt / FCF | — | 7.30 | 6.71 | 14.19 | 1.32 | 1.17 | 3.14 | 4.97 | 2.98 | 2.90 | 2.77 |
| Interest Coverage | 3.82 | 3.82 | 3.60 | 1.48 | 29.05 | 19.83 | 5.86 | 8.30 | 10.03 | 10.69 | 8.04 |
PFE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.16x means Pfizer Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 0.91x to 1.16x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.16 | 1.16 | 1.17 | 0.91 | 1.22 | 1.40 | 1.35 | 0.88 | 1.57 | 1.35 | 1.25 |
| Quick Ratio | 0.87 | 0.87 | 0.92 | 0.69 | 1.00 | 1.19 | 1.04 | 0.69 | 1.33 | 1.10 | 1.03 |
| Cash Ratio | 0.37 | 0.37 | 0.48 | 0.27 | 0.54 | 0.73 | 0.47 | 0.26 | 0.59 | 0.66 | 0.57 |
| Asset Turnover | — | 0.30 | 0.30 | 0.26 | 0.51 | 0.45 | 0.27 | 0.25 | 0.34 | 0.31 | 0.31 |
| Inventory Turnover | 1.74 | 1.74 | 2.01 | 2.87 | 4.26 | 3.80 | 1.46 | 1.79 | 2.13 | 2.08 | 2.35 |
| Days Sales Outstanding | — | 69.26 | 84.77 | 95.27 | 52.86 | 70.70 | 97.95 | 84.29 | 77.56 | 78.29 | 77.85 |
PFE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Pfizer Inc. returns 6.8% to shareholders annually primarily through dividends. The payout ratio exceeds 100% at 125.8%, meaning the company is paying out more than it earns — this level is unsustainable long-term without earnings recovery. The earnings yield of 5.4% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 6.8% | 6.9% | 6.3% | 5.6% | 3.1% | 2.6% | 4.1% | 3.8% | 3.2% | 3.7% | 3.9% |
| Payout Ratio | 125.8% | 125.8% | 118.6% | 433.5% | 28.6% | 39.4% | 92.1% | 49.4% | 71.5% | 35.9% | 101.4% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.4% | 5.5% | 5.3% | 1.3% | 10.7% | 6.6% | 4.4% | 7.7% | 4.5% | 10.2% | 3.8% |
| FCF Yield | 6.3% | 6.4% | 6.5% | 2.9% | 8.9% | 8.9% | 5.6% | 4.7% | 5.5% | 6.9% | 7.3% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.7% | 0.0% | 0.0% | 4.2% | 4.9% | 2.4% | 2.6% |
| Total Shareholder Yield | 6.8% | 6.9% | 6.3% | 5.6% | 3.7% | 2.6% | 4.1% | 8.0% | 8.2% | 6.1% | 6.5% |
| Shares Outstanding | — | $5.7B | $5.7B | $5.7B | $5.7B | $5.7B | $5.6B | $5.7B | $6.0B | $6.1B | $6.2B |
Peer Comparison
Compare PFE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PFEYou | $143B | 18.5 | 10.3 | 15.8 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 JNJ | $550B | 39.4 | 19.1 | 27.7 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
 MRK | $281B | 15.6 | 10.8 | 22.8 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 ABBV | $383B | 91.4 | 15.8 | 21.5 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 LLY | $1.0T | 47.8 | 34.3 | 115.6 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 BMY | $110B | 15.7 | 8.9 | 8.6 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 AZN | $271B | 26.7 | 15.2 | 23.1 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
 NVS | $281B | 20.5 | 13.7 | 15.9 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
 AMGN | $182B | 23.7 | 14.4 | 22.5 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
 GILD | $154B | 18.3 | 11.8 | 16.2 | 78.8% | 39.7% | 40.7% | 23.2% | 1.7 |
 BIIB | $29B | 22.3 | 11.7 | 14.2 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into PFE consensus models and risk factors.
View Analysis
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
PFE — Frequently Asked Questions
Quick answers to the most common questions about buying PFE stock.
What is Pfizer Inc.'s P/E ratio?
Pfizer Inc.'s current P/E ratio is 18.5x. The historical average is 26.5x. This places it at the 47th percentile of its historical range.
What is Pfizer Inc.'s EV/EBITDA?
Pfizer Inc.'s current EV/EBITDA is 10.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.7x.
What is Pfizer Inc.'s ROE?
Pfizer Inc.'s return on equity (ROE) is 8.9%. The historical average is 20.2%.
Is PFE stock overvalued?
Based on historical data, Pfizer Inc. is trading at a P/E of 18.5x. This is at the 47th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Pfizer Inc.'s dividend yield?
Pfizer Inc.'s current dividend yield is 6.81% with a payout ratio of 125.8%.
What are Pfizer Inc.'s profit margins?
Pfizer Inc. has 70.3% gross margin and 24.7% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Pfizer Inc. have?
Pfizer Inc.'s Debt/EBITDA ratio is 3.3x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.